Cargando…

Preanalytical stability of plasma biomarkers for Alzheimer's disease pathology

INTRODUCTION: Plasma tests have demonstrated high diagnostic accuracy for identifying Alzheimer's disease pathology. To facilitate the transition to clinical utility, we assessed whether plasma storage duration and temperature affect the biomarker concentrations. METHODS: Plasma samples from 13...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sunde, Anita L., Alsnes, Ingvild V., Aarsland, Dag, Ashton, Nicholas J., Tovar‐Rios, Diego A., De Santis, Giovanni, Blennow, Kaj, Zetterberg, Henrik, Kjosavik, Svein R.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2023
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10182363/ https://www.ncbi.nlm.nih.gov/pubmed/37192842 http://dx.doi.org/10.1002/dad2.12439

Ejemplares similares

Plasma p-tau181 accurately predicts Alzheimer’s disease pathology at least 8 years prior to post-mortem and improves the clinical characterisation of cognitive decline
por: Lantero Rodriguez, Juan, et al.
Publicado: (2020)

Spitting image: can saliva biomarkers reflect Alzheimer's disease?
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Salivary Biomarkers for Alzheimer’s Disease and Related Disorders
por: Ashton, Nicholas J., et al.
Publicado: (2019)

Cerebrospinal Fluid Levels of sAPPα and sAPPβ in Lewy Body and Alzheimer's Disease: Clinical and Neurochemical Correlates
por: Mulugeta, Ezra, et al.
Publicado: (2011)

Increased plasma neurofilament light chain concentration correlates with severity of post-mortem neurofibrillary tangle pathology and neurodegeneration
por: Ashton, Nicholas J., et al.
Publicado: (2019)

The Past and the Future of Alzheimer’s Disease Fluid Biomarkers(1)
por: Blennow, Kaj, et al.
Publicado: (2018)

Blood Biomarkers for Alzheimer’s Disease in Down Syndrome
por: Montoliu-Gaya, Laia, et al.
Publicado: (2021)

Is it time for biomarker-based diagnostic criteria for prodromal Alzheimer's disease?
por: Blennow, Kaj, et al.
Publicado: (2010)

Moving fluid biomarkers for Alzheimer’s disease from research tools to routine clinical diagnostics
por: Zetterberg, Henrik, et al.
Publicado: (2021)

Biomarkers for tau pathology
por: Schöll, Michael, et al.
Publicado: (2019)

Neuroinflammation Screening in Immunotherapy Trials against Alzheimer's Disease
por: Andreasen, Niels, et al.
Publicado: (2010)

The past and the future of Alzheimer's disease CSF biomarkers—a journey toward validated biochemical tests covering the whole spectrum of molecular events
por: Blennow, Kaj, et al.
Publicado: (2015)

Lessons from Multicenter Studies on CSF Biomarkers for Alzheimer's Disease
por: Mattsson, Niklas, et al.
Publicado: (2010)

Plasma GFAP is an early marker of amyloid-β but not tau pathology in Alzheimer’s disease
por: Pereira, Joana B, et al.
Publicado: (2021)

Apolipoprotein B is a novel marker for early tau pathology in Alzheimer's disease
por: Picard, Cynthia, et al.
Publicado: (2021)

Plasma glial fibrillary acidic protein detects Alzheimer pathology and predicts future conversion to Alzheimer dementia in patients with mild cognitive impairment
por: Cicognola, Claudia, et al.
Publicado: (2021)

Fluid biomarkers in Alzheimer’s disease – current concepts
por: Rosén, Christoffer, et al.
Publicado: (2013)

Are neuropsychiatric symptoms in dementia linked to CSF biomarkers of synaptic and axonal degeneration?
por: Bloniecki, Victor, et al.
Publicado: (2020)

Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease
por: Mattsson, Niklas, et al.
Publicado: (2017)

Use of theragnostic markers to select drugs for phase II/III trials for Alzheimer disease
por: Zetterberg, Henrik, et al.
Publicado: (2010)

Association of neurogranin gene expression with Alzheimer's disease pathology in the perirhinal cortex
por: Sun, Xiaoyan, et al.
Publicado: (2021)

Cerebrospinal fluid biomarkers for Alzheimer disease and subcortical axonal damage in 5,542 clinical samples
por: Skillbäck, Tobias, et al.
Publicado: (2013)

Blood neurofilament light in remote settings: Alternative protocols to support sample collection in challenging pre‐analytical conditions
por: Simrén, Joel, et al.
Publicado: (2021)

Detection of early-stage Alzheimer’s pathology using blood-based autoantibody biomarkers in elderly hip fracture repair patients
por: DeMarshall, Cassandra, et al.
Publicado: (2019)

Myo-inositol changes precede amyloid pathology and relate to APOE genotype in Alzheimer disease
por: Voevodskaya, Olga, et al.
Publicado: (2016)

Plasma phosphorylated tau181 and neurodegeneration in Alzheimer’s disease
por: Hansson, Oskar, et al.
Publicado: (2020)

Editorial: Blood Biomarkers of Neurodegenerative Diseases
por: Karikari, Thomas K., et al.
Publicado: (2022)

Classification accuracy of blood-based and neurophysiological markers in the differential diagnosis of Alzheimer’s disease and frontotemporal lobar degeneration
por: Benussi, Alberto, et al.
Publicado: (2022)

Tracking reactive astrogliosis in autosomal dominant and sporadic Alzheimer’s disease with multi-modal PET and plasma GFAP
por: Chiotis, Konstantinos, et al.
Publicado: (2023)

Plasma neurofilament light and phosphorylated tau 181 as biomarkers of Alzheimer’s disease pathology and clinical disease progression
por: Clark, Christopher, et al.
Publicado: (2021)

Delineating Amyloid Plaque Associated Neuronal Sphingolipids in Transgenic Alzheimer’s Disease Mice (tgArcSwe) Using MALDI Imaging Mass Spectrometry
por: Kaya, Ibrahim, et al.
Publicado: (2016)

Differences between blood and cerebrospinal fluid glial fibrillary Acidic protein levels: The effect of sample stability
por: Simrén, Joel, et al.
Publicado: (2022)

The role of the pathology department in the preanalytical phase of molecular analyses
por: Susman, Sergiu, et al.
Publicado: (2018)

Synaptic Molecular and Neurophysiological Markers Are Independent Predictors of Progression in Alzheimer’s Disease
por: Smailovic, Una, et al.
Publicado: (2021)

Longitudinal cerebrospinal fluid biomarker measurements in preclinical sporadic Alzheimer's disease: A prospective 9-year study
por: Stomrud, Erik, et al.
Publicado: (2015)

Body mass index trajectories and associations with cognitive decline in people with Lewy body dementia and Alzheimer's disease
por: Borda, Miguel G., et al.
Publicado: (2022)

Preanalytical Stability of CSF Total and Oligomeric Alpha-Synuclein
por: Abdi, Ilham Y., et al.
Publicado: (2021)

Biomarkers for Microglial Activation in Alzheimer's Disease
por: Lautner, Ronald, et al.
Publicado: (2011)

Plasma tau levels in Alzheimer's disease
por: Zetterberg, Henrik, et al.
Publicado: (2013)

Plasma p-tau231: a new biomarker for incipient Alzheimer’s disease pathology
por: Ashton, Nicholas J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_v86j6j0dt51k03fj62gfvs77ij